Celia and Peter discuss how CILcare-CBSET built the partnership and fostered innovation to accelerate the development of auditory therapies<\/strong>. They also shed light on the connection between hearing loss and other diseases<\/strong>, sharing their vision of the future for hearing loss treatment.<\/strong><\/p>\n We warmly thank Brian Taylor and his team for setting up this interview which emphasizes exciting research perspectives in the field of hearing disorders.<\/p>\n Celia BELLINE, CILcare\u2019s CEO<\/a>: Celia <\/strong>has over 20 years\u2019 experience in the pharmaceutical industry. She worked as the global head of clinical trial logistics and supply chains in\u00a0Sanofi<\/strong>\u00a0R&D, was a permanent member of\u00a0clinical strategic<\/strong>\u00a0committees<\/strong>, and the Director of projects dealing with major\u00a0chronic diseases<\/strong>\u00a0associated with\u00a0aging<\/strong>, where she developed her interest and expertise in\u00a0hearing disorders<\/strong>. She trained at ESSEC and London Business Schools, in addition to holding several master\u2019s degrees in project management, industrial strategy and health environment. In 2014, Celia along with Drs. Sylvie Pucheu & Marie-Pierre Pasdelou, founded CILcare, a Smart R&D platform dedicated to the acceleration and development of novel therapies to prevent and treat ear disorders, with offices in Boston, MA, France, and Denmark.<\/p>\n Peter MARKHAM, CBSET\u2019s CEO<\/a>:<\/strong>\u00a0Peter<\/strong> has 30 years of management and regulatory experience in GLP contract research<\/strong>. Prior to cofounding CBSET in 2006, he was general manager of the Worcester\/Southbridge division of Charles River Laboratories, a multi-disciplinary pre-clinical business unit which serviced the Toxicology, Pharmacology, Surgery, Metabolism, Pharmacokinetics, and Bioanalytical Chemistry markets. Previously, he served as a senior executive in leadership roles at various research companies including Genzyme Transgenics, Primedica, BioDevelopment Laboratories, and Arthur D. Little. He has broad expertise in both drug and device development<\/strong> with over two decades of scientific leadership in drug metabolism, pharmacokinetics, bioanalytical chemistry, and the application of these scientific disciplines to the development of combination products. Mr. Markham holds a BS and MS in Bioanalytical Chemistry from University of Massachusetts.<\/p>\nAbout the panel:<\/u><\/h5>\n